Kidney Neoplasms, Metastatic Renal Cell Cancer
Conditions
Keywords
renal cell carcinoma, sunitinib, metastatic, schedule, toxicity, safety
Brief summary
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. Thereafter, sunitinib is initiated 50 mg/day; regimen 4/6 (Marketing Authorisation Indication), 4 weeks on alternating with 2 weeks off As soon as a dose or schedule adjustment is required, regardless of cause, the patient will be randomised 1/1: * Either into arm A and will receive 37.5mg of Sunitinib per day by the 4/6 regimen (in accordance with the Marketing Authorisation); 4 weeks on alternating with 2 weeks off * Or into arm B and will receive 50mg of Sunitinib per day by the 2/3 regimen (investigational arm); 2 weeks on alternating with 1 week off
Interventions
DRUGSunitinib
Sponsors
Pfizer
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Men or women over 18 years old * Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication * Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component * Karnofsky performance status ≥ 70% * Adequate organ function: * Absolute neutrophil (N) count ≥ 1 500 / µL * Platelets ≥ 100 000 / µL * Haemoglobin ≥ 10 g/dL * Adjusted serum calcium ≤ 2.6 mmol/L * Creatinine clearance ≥ 30 mL/min (by the MDRD formula) * Total bilirubin ≤ 1.5 x ULN (upper limit of the normal range) * AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN OR AST and ALT ≤ 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase Key
Exclusion criteria
* Renal carcinoma with no clear cell component. * Previous systemic treatment for the RCC regardless of type (including targeted therapy, immunotherapy, chemotherapy, hormone or experimental therapy). Previous or concomitant treatment with a bisphosphonate or denosumab is allowed. * Patients whose clinical state and comorbidities are not consistent with administration of Sunitinib at the initial dose of 50mg/day 4 weeks out of 6. * Grade 3 haemorrhage within 4 weeks before starting treatment with Sunitinib (according to the NCI-CTCAE toxicity score version 3.0). * The presence of a past history of cancer in the 3 years before inclusion into the study * Major surgery within 4 weeks before sunitinib initiation * Past history of symptomatic cerebral metastases, spinal cord compression or meningeal carcinomatosis. Patients with cerebral metastases discovered incidentally on imaging and who are asymptomatic are not excluded if these metastases have been treated (radiotherapy and/or surgery) with a period of at least 4 weeks between the end of treatment and inclusion into the study and no clinical or radiological signs of relapse, and corticosteroid dose is not exceeding 10mg/day of prednisone or equivalent. Subjects will be excluded if subjects have signs of grade ≥ 2 treatment-related complications. * Any of the following features within 6 months of the administration of Sunitinib: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack. * Pulmonary embolism or deep vein thrombosis within 3 months of inclusion (unless it's stable, asymptomatic and treated with a low molecular weight heparin for at least 6 weeks before inclusion). * Any known acute or chronic disorder (such as severe chronic obstructive pulmonary disease) which in the opinion of the investigator could impact on the patient's capacity to receive the study treatment or make interpretation of toxicity or adverse events difficult. * Known HIV infection. * History of chronic active hepatitis including subjects who are carriers of the hepatitis B (HBV) or hepatitis C (HCV) virus. * Existence of uncontrolled infection. * Uncontrolled hypertension defined as a blood pressure of \> 150 mmHg systolic or \> 100 mmHg diastolic despite optimal anti-hypertensive therapy (blood pressure must be controlled at inclusion).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MDT (median duration of treatment) | 12 mo | The primary objective of this study is to estimate the median duration of treatment in each treatment group (arm A vs arm B) calculated from sunitinib initiation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS (overall survival) | 30 months | To estimate overall survival in patients included in each of the groups and in the overall population included in this study. |
| duration of sunitinib post randomization | 12 months | Estimation of the time between date of randomization and sunitinib arrest (for any reason) in the two treatment arms. |
| time to randomization | 4 months | To estimate the time to randomization defined as the time between the date of sunitinib initiation and the date of randomization. |
| PFS (progression-free survival) | 12 months | To estimate progression-free survival in patients included in each of the groups and in the overall population included in this study. |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 24 months | To assess safety profile before and after randomization. |
| QOL (quality of life) | 24 months | To assess health-related quality of life since sunitinib is started (before randomization, at the time of randomization and after randomization) |
| ORR (objective response rate) | 6 months | To measure the objective response rate according to RECIST 1.1 criteria. |
Countries
France
Outcome results
None listed